Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model

2013 ◽  
Vol 149 (3) ◽  
pp. 487-497 ◽  
Author(s):  
Lucas Y.H. Goh ◽  
Jody Hobson-Peters ◽  
Natalie A. Prow ◽  
Joy Gardner ◽  
Helle Bielefeldt-Ohmann ◽  
...  
2011 ◽  
Vol 85 (14) ◽  
pp. 7005-7019 ◽  
Author(s):  
M. C. Sabo ◽  
V. C. Luca ◽  
J. Prentoe ◽  
S. E. Hopcraft ◽  
K. J. Blight ◽  
...  

2021 ◽  
Author(s):  
Fatima Amanat ◽  
Shirin Strohmeier ◽  
Wen-Hsin Lee ◽  
Sandhya Bangaru ◽  
Andrew B Ward ◽  
...  

After first emerging in December 2019 in China, severe acute respiratory syndrome 2 (SARS-CoV-2) has since caused a pandemic leading to millions of infections and deaths worldwide. Vaccines have been developed and authorized but supply of these vaccines is currently limited. With new variants of the virus now emerging and spreading globally, it is essential to develop therapeutics that are broadly protective and bind conserved epitopes in the receptor binding domain (RBD) or the whole spike of SARS-CoV-2. In this study, we have generated mouse monoclonal antibodies (mAbs) against different epitopes on the RBD and assessed binding and neutralization against authentic SARS-CoV-2. We have demonstrated that antibodies with neutralizing activity, but not non-neutralizing antibodies, lower viral titers in the lungs when administered in a prophylactic setting in vivo in a mouse challenge model. In addition, most of the mAbs cross-neutralize the B.1.351 as well as the B.1.1.7 variants in vitro.


mAbs ◽  
2015 ◽  
Vol 7 (6) ◽  
pp. 1178-1194 ◽  
Author(s):  
Shirley Lam ◽  
Min Nyo ◽  
Patchara Phuektes ◽  
Chow Wenn Yew ◽  
Yee Joo Tan ◽  
...  
Keyword(s):  

2011 ◽  
Vol 186 (5) ◽  
pp. 3258-3264 ◽  
Author(s):  
Lucile Warter ◽  
Chia Yin Lee ◽  
Rekha Thiagarajan ◽  
Marc Grandadam ◽  
Serge Lebecque ◽  
...  

1998 ◽  
Vol 66 (3) ◽  
pp. 1057-1062 ◽  
Author(s):  
Rui Rong Yuan ◽  
Gadi Spira ◽  
Jin Oh ◽  
Melia Paizi ◽  
Arturo Casadevall ◽  
...  

ABSTRACT The isotype and epitope specificities of antibodies both contribute to the efficacy of antibodies that mediate immunity toCryptococcus neoformans, but the relationship between these properties is only partially understood. In this study, we analyzed the efficacy of protection of two sets of immunoglobulin G (IgG) isotype switch variants from two IgG3 monoclonal antibodies (MAbs) which are either not protective or disease enhancing, depending on the mouse model used. The two IgG3 MAbs 3E5 and 4H3 have different epitope specificities. Protection experiments were done with A/JCr mice infected intravenously with C. neoformans and administered with 3E5 IgG3 and its IgG1, IgG2a, and IgG2b switch variants. These experiments revealed that IgG1, IgG2b, and IgG2a were each more effective than IgG3. For 4H3 IgG3 and its IgG1 and IgG2b switch variants, the relative efficacy was IgG2b > IgG1 >> IgG3. The combination of 3E5 IgG3 and 4H3 IgG3 was more deleterious than either IgG3 alone. All IgG isotypes were opsonic for mouse bronchoalveolar cells, with the relative efficacy being IgG2b > IgG2a > IgG1 > IgG3. These results (i) confirm that a nonprotective IgG3 MAb can be converted to a protective MAb by isotype switching, (ii) indicate that the efficacy of protection of an IgG1 MAb can be increased by isotype switching to another subclass, (iii) show that protective and nonprotective IgG MAbs are opsonic, and (iv) provide additional evidence for the concept that the efficacy of the antibody response to C. neoformans is dependent on the type of MAb elicited.


1999 ◽  
Vol 73 (6) ◽  
pp. 4670-4677 ◽  
Author(s):  
Reet Kurg ◽  
Jüri Parik ◽  
Erkki Juronen ◽  
Tiina Sedman ◽  
Aare Abroi ◽  
...  

ABSTRACT The bovine papillomavirus type 1 (BPV-1) E2 protein is the master regulator of papillomavirus replication and transcription. We have raised a panel of monoclonal antibodies (MAbs) against the BPV-1 E2 protein and used them to probe the structure and function of the protein. Five MAbs reacted with linear epitopes, and four MAbs recognized conformation-dependent epitopes which mapped within the C-terminal DNA-binding and dimerization domain. MAb 1E2 was able to recognize the replication- and transactivation-defective but not the competent conformation of the transactivation domain of the E2 protein. MAb 5H4 prevented efficiently the formation of E2-DNA as well as E2-dependent E1-E2-origin complexes and also dissociated preformed complexes in a concentration-dependent manner. Cotransfection of several MAbs with the BPV-1 minimal origin plasmid pUCAlu into CHO4.15 cells resulted in a dose-dependent inhibition of replication. Inhibition of replication by MAb 5H4 and the Fab′ fragment of 5H4 correlated with their ability to dissociate the E2 protein from the DNA. MAb 3F12 and MAbs 1H10 and 1E4, directed against the hinge region, were also capable of inhibiting BPV-1 origin replication in CHO4.15 cells. However, the Fab′ fragments of 1H10 and 3F12 had no effect in the transient replication assay. These data suggest that MAbs directed against the hinge region sterically hinder the inter- or intramolecular interactions required for the replication activity of the E2 protein.


Sign in / Sign up

Export Citation Format

Share Document